Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Status:
Terminated
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in
combination with sorafenib for subjects with unresectable HCC who have received no prior
systemic therapy for HCC. The dose escalation phase of the study will explore several dose
levels of CC-122 in combination with sorafenib, followed by an expansion part of the study
using the optimal combination dose regimen.